User login
Key clinical point: The risk for uterine diseases was significantly increased in premenopausal women with breast cancer (BC) who received tamoxifen as an adjuvant hormone therapy.
Major finding: Compared with patients who did not receive adjuvant hormone therapy, those who received tamoxifen had a significantly higher risk for endometrial cancer (hazard ratio [HR] 3.77; 95% CI 3.04-4.66), endometrial polyps (HR 3.90; 95% CI 3.65-4.16), hyperplasia (HR 5.56; 95% CI 5.06-6.12), and other uterine cancers (HR 2.27; 95% CI 1.54-3.33).
Study details: Findings are from a nationwide, retrospective, longitudinal cohort study including 78,320 premenopausal women with BC who received (tamoxifen only; n = 34,637) or did not receive (n = 43,683) an adjuvant hormone treatment.
Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.
Source: Ryu KJ et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022 5(11):e2243951 (Nov 28). Doi: 10.1001/jamanetworkopen.2022.43951
Key clinical point: The risk for uterine diseases was significantly increased in premenopausal women with breast cancer (BC) who received tamoxifen as an adjuvant hormone therapy.
Major finding: Compared with patients who did not receive adjuvant hormone therapy, those who received tamoxifen had a significantly higher risk for endometrial cancer (hazard ratio [HR] 3.77; 95% CI 3.04-4.66), endometrial polyps (HR 3.90; 95% CI 3.65-4.16), hyperplasia (HR 5.56; 95% CI 5.06-6.12), and other uterine cancers (HR 2.27; 95% CI 1.54-3.33).
Study details: Findings are from a nationwide, retrospective, longitudinal cohort study including 78,320 premenopausal women with BC who received (tamoxifen only; n = 34,637) or did not receive (n = 43,683) an adjuvant hormone treatment.
Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.
Source: Ryu KJ et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022 5(11):e2243951 (Nov 28). Doi: 10.1001/jamanetworkopen.2022.43951
Key clinical point: The risk for uterine diseases was significantly increased in premenopausal women with breast cancer (BC) who received tamoxifen as an adjuvant hormone therapy.
Major finding: Compared with patients who did not receive adjuvant hormone therapy, those who received tamoxifen had a significantly higher risk for endometrial cancer (hazard ratio [HR] 3.77; 95% CI 3.04-4.66), endometrial polyps (HR 3.90; 95% CI 3.65-4.16), hyperplasia (HR 5.56; 95% CI 5.06-6.12), and other uterine cancers (HR 2.27; 95% CI 1.54-3.33).
Study details: Findings are from a nationwide, retrospective, longitudinal cohort study including 78,320 premenopausal women with BC who received (tamoxifen only; n = 34,637) or did not receive (n = 43,683) an adjuvant hormone treatment.
Disclosures: This study was supported by a National Research Foundation of Korea grant. The authors declared no conflicts of interest.
Source: Ryu KJ et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open. 2022 5(11):e2243951 (Nov 28). Doi: 10.1001/jamanetworkopen.2022.43951